Syndax axatilimab misses primary endpoint in Phase 2 IPF trial, drops further development in indication

Syndax reported topline results from its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis. The study missed its primary goal, leading Syndax to drop further development of axatilimab in idiopathic pulmonary fibrosis. Safety looked comparable to placebo, with no new safety signals flagged. Ongoing axatilimab trials in chronic graft-versus-host disease remain on track, with additional results expected later this year and in early 2028. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Syndax Pharmaceuticals Inc. published the original content used to generate this news brief via (Ref. ID: 202610121601PRIMZONEFULLFEED9844118) on October 12, 2026, and is solely responsible for the information contained therein. (C)